Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1877085 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL14224174 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL16104131 | 0.89 | SLC6A2 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL297266 | 0.89 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL3740415 | 0.87 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL15667928 | 0.87 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL1840824 | 0.87 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL10653802 | 0.86 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL27957684 | 0.84 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL30948823 | 0.83 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113179590-A | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-107208279-B | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10174428-B2 | Etchant, replenishment solution and method for forming copper wiring | MEC COMPANY LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-10144849-B2 | Polishing composition and polishing method using the same | FUJIMI INCORPORATED (JP) | 2018-12-04 | — | — | US | disclosed |
| US-20170260632-A1 | ETCHANT, REPLENISHMENT SOLUTION AND METHOD FOR FORMING COPPER WIRING | MEC COMPANY LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| CN-102884062-B | Aminopyrimidine inhibitors of kinases | 嘉世高制药公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-103930426-B | As [1,2,3] triazols [4, the 5-D] pyrimidine derivatives of Cannabined receptor 2 activators | HOFFMAN-LA ROCHE LTD. (CH) | 2016-05-11 | — | — | CN | disclosed |
| EP-3008055-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| EP-2247588-B1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7129247-B2 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| US-20050014746-A1 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-supressive agents | ICOS CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014746-A1 | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-supressive agents | ICAM1, VCAM1, CD47 | SLC6A4 4150/4885SLC6A2 4393/4885SLC6A3 3521/4885 |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | SLC6A4 1157/4885SLC6A2 792/4885SLC6A3 1729/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | SLC6A4 166/4885SLC6A2 181/4885SLC6A3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.